Global Infectious Diseases Collaboration and Licensing Agreements Analysis Report 2023: Company A-Z, Headline Value, Upfront, Milestone, Royalties, Therapeutic Area, Technology Type

Dublin, Nov. 16, 2023 (GLOBE NEWSWIRE) — The “Infectious Diseases Collaboration and Licensing Deals 2016-2023” report has been added to ResearchAndMarkets.com’s offering.

Infectious Diseases Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the infectious diseases deals entered into by the worlds leading biopharma companies.

This fully revised and updated report offers comprehensive details of infectious diseases deals spanning from 2016 to 2023. It provides valuable insights into the terms of these deals as they were announced between the involved parties. This data is crucial for gaining a deeper understanding of the payment and other terms negotiated in these agreements.

Understanding the flexibility and intricacies of the deal terms negotiated by potential partners offers essential insights into the negotiation process. It provides clarity on what can be expected during the negotiation of these terms. While many companies may focus on payment clauses, the critical details lie in understanding how payments are triggered and how rights are transferred. Contract documents provide this level of insight, which may not be readily available through press releases and databases.

This report includes a comprehensive listing of collaboration and licensing deals announced since 2016, sourced from the Current Agreements deals and alliances database. It encompasses financial terms where available and includes links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by the collaborating companies and their partners.

Additionally, the report offers a comprehensive deal directory, organized alphabetically by company and technology type. Each deal title is linked via Weblink to an online version of the deal record and, where available, the contract document. This feature provides convenient access to each contract document as needed.

Chapter Highlights

The initial chapters of this report provide an orientation of infectious diseases dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in infectious diseases dealmaking.

Chapter 3 covers the financial deal terms for deals signed in the infectious diseases field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.

Chapter 4 provides a review of the top 25 most active biopharma companies in infectious diseases dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive and detailed review of infectious diseases deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of infectious diseases deals listed by theraeutic target.

The report also includes numerous table and figures that illustrate the trends and activities in infectious diseases deal making since 2016.

Infectious Diseases Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse infectious diseases collaboration and licensing deals
• Benchmark analysis – identify market value of transactions
• Financials terms – upfront, milestone, royalties
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents – insights into deal structures
• Due diligence – assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Infectious Diseases Collaboration and Licensing Deals includes:

• Trends in infectious diseases dealmaking in the biopharma industry
• Overview of collaboration and licensing deal structure
• Directory of infectious diseases deal records covering pharmaceutical and biotechnology
• The leading infectious diseases deals by value
• Most active infectious diseases licensing dealmakers

In Infectious Diseases Collaboration and Licensing Deals, the available deals are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Key Topics Covered:

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in infectious diseases dealmaking
2.1. Introduction
2.2. Infectious diseases partnering over the years
2.3. Infectious diseases partnering by deal type
2.4. Infectious diseases partnering by industry sector
2.5. Infectious diseases partnering by stage of development
2.6. Infectious diseases partnering by technology type
2.7. Infectious diseases partnering by therapeutic indication

Chapter 3 – Financial deal terms for infectious diseases partnering
3.1. Introduction
3.2. Disclosed financials terms for infectious diseases partnering
3.3. Infectious diseases partnering headline values
3.4. Infectious diseases deal upfront payments
3.5. Infectious diseases deal milestone payments
3.6. Infectious diseases royalty rates

Chapter 4 – Leading infectious diseases deals and dealmakers
4.1. Introduction
4.2. Most active in infectious diseases partnering
4.3. List of most active dealmakers in infectious diseases
4.4. Top infectious diseases deals by value

Chapter 5 – Infectious diseases contract document directory
5.1. Introduction
5.2. Infectious diseases partnering deals where contract document available

Chapter 6 – Infectious diseases dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by infectious diseases therapeutic target

Deal Directory
Deal directory – Infectious diseases deals by company A-Z 2016 to 2023
Deal directory – Infectious diseases deals by technology type 2016 to 2023

For more information about this report visit https://www.researchandmarkets.com/r/ispo41

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.